These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2162 related articles for article (PubMed ID: 29923025)

  • 1. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
    Nielsen S; Germanos R; Weier M; Pollard J; Degenhardt L; Hall W; Buckley N; Farrell M
    Curr Neurol Neurosci Rep; 2018 Feb; 18(2):8. PubMed ID: 29442178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical use of cannabis products: Lessons to be learned from Israel and Canada.
    Ablin J; Ste-Marie PA; Schäfer M; Häuser W; Fitzcharles MA
    Schmerz; 2016 Feb; 30(1):3-13. PubMed ID: 26767992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Koppel BS; Brust JC; Fife T; Bronstein J; Youssof S; Gronseth G; Gloss D
    Neurology; 2014 Apr; 82(17):1556-63. PubMed ID: 24778283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis and multiple sclerosis.
    Fragoso YD; Carra A; Macias MA
    Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.
    Breijyeh Z; Jubeh B; Bufo SA; Karaman R; Scrano L
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33562446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding Cannabis-Based Therapeutics in Sports Medicine.
    Maurer GE; Mathews NM; Schleich KT; Slayman TG; Marcussen BL
    Sports Health; 2020; 12(6):540-546. PubMed ID: 32936058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis and cannabinoids.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):97-8. PubMed ID: 27466748
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of medical-grade cannabis in patients non-responders to Nabiximols.
    Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
    J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs.
    Parmar JR; Forrest BD; Freeman RA
    Res Social Adm Pharm; 2016; 12(4):638-54. PubMed ID: 26443472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G; Constantinescu CS
    Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
    Krcevski-Skvarc N; Wells C; Häuser W
    Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
    Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
    Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
    S G; Hb S; K L; R T; Bs R; Ps S; F S; Ab O
    Mult Scler Relat Disord; 2021 Feb; 48():102708. PubMed ID: 33387864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids: Medical implications.
    Schrot RJ; Hubbard JR
    Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Marihuana and cannobinoids as medicaments].
    Tkaczyk M; Florek E; Piekoszewski W
    Przegl Lek; 2012; 69(10):1095-7. PubMed ID: 23421098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 109.